Beta-Blocker Influences on Inflammatory and Neural Responses to Stress - Trial NCT06263452
Access comprehensive clinical trial information for NCT06263452 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of North Carolina, Chapel Hill and is currently Not yet recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of North Carolina, Chapel Hill
Timeline & Enrollment
Phase 4
Mar 01, 2024
Mar 01, 2026
Primary Outcome
Change in levels of pro-inflammatory cytokine interleukin-6 in response to social stress,Change in levels of inflammatory gene expression in response to social stress
Summary
The purpose of this study is to map the neural and molecular mechanisms underlying
 psychological stress-induced changes in inflammation which could reveal new targets for
 intervention to reduce the risk of cardiovascular disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06263452
Non-Device Trial